Apellis Pharmaceuticals, Inc.
APLS
Rang in aandelen
#3335
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical... Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
Aandeelprijs
$41.03
Laatst gesynchroniseerd: 2026-05-15
Marktkapitalisatie
$5.25B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
44.93%
Land
US
Handel Apellis Pharmaceuticals, Inc. (APLS)
Categorie
Healthcare
Omzet van Apellis Pharmaceuticals, Inc. (APLS)
Omzet in Mar 2026 TTM: $1.11B
Volgens de laatste financiële rapporten van Apellis Pharmaceuticals, Inc. bedraagt de huidige omzet van het bedrijf (TTM) $1.11B. In 2023 behaalde het bedrijf een omzet van $396.59M een stijging ten opzichte van de omzet in het jaar 2022, die $75.42M bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Apellis Pharmaceuticals, Inc. van 2013 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $1.11B | 41.45% |
| 2024 | $781.37M | 97.02% |
| 2023 | $396.59M | 425.83% |
| 2022 | $75.42M | 13.31% |
| 2021 | $66.56M | -73.44% |
| 2020 | $250.65M | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $12.62B | 1,042.18% |
US
|
|
| $2.23B | 101.58% |
US
|
|
| $15.74B | 1,324.47% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 444.77% |
NL
|
